Diagnostic grading system developed for cancer-related weight loss

This article originally appeared here.
Share this content:
Diagnostic Criteria Developed for Cancer-Linked Weight Loss
Diagnostic Criteria Developed for Cancer-Linked Weight Loss

(HealthDay News) -- A grading system has been developed for clinically important weight loss (WL) in patients with cancer, which includes the independent prognostic significance of body mass index (BMI) and percent WL, according to research published online Nov. 24 in the Journal of Clinical Oncology.

Lisa Martin, R.D., from the University of Alberta in Edmonton, Canada, and colleagues used data from 8,160 Canadian and European patients with cancer to produce definitions of clinically important WL. A grading system was developed using the relationships between BMI and percent WL with overall survival.

The researchers found that both BMI and percent WL independently predicted survival (P < 0.01). Across five categories of BMI and five categories of percent WL there were differences in survival (both P < 0.001). The longest survival was seen for weight-stable patients with BMI ≥25.0 kg/m² (grade 0, 20.9 months); percent WL values associated with lowered categories of BMI correlated with shorter survival (grade 1, 14.6 months; grade 2, 10.8 months; grade 3, 7.6 months; and grade 4, 4.3 months; P < 0.001). There was survival discrimination by grade within specific cancers, stages, ages, and performance status, as well as in an independent validation sample of 2,963 patients.

"We systematically developed a cancer WL grading system that incorporates the two dimensions of percent WL and BMI and links them to survival," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs